These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35726190)

  • 1. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
    Taherian M; Wang H
    Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society.
    Wang H; Chetty R; Hosseini M; Allende DS; Esposito I; Matsuda Y; Deshpande V; Shi J; Dhall D; Jang KT; Kim GE; Luchini C; Graham RP; Reid MD; Basturk O; Hruban RH; Krasinskas A; Klimstra DS; Adsay V;
    Am J Surg Pathol; 2022 Jun; 46(6):754-764. PubMed ID: 34889852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications.
    Nagaria TS; Wang H; Chatterjee D; Wang H
    Arch Pathol Lab Med; 2020 Jul; 144(7):838-845. PubMed ID: 32023088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy.
    Sohn AJ; Taherian M; Katz MHG; Prakash LR; Chatterjee D; Wang H; Kim M; Tzeng CD; Lee JE; Ikoma N; Rashid A; Wolff RA; Zhao D; Koay EJ; Sun R; Maitra A; Wang H
    Am J Surg Pathol; 2023 Apr; 47(4):421-430. PubMed ID: 36746143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems.
    Vazzano J; Frankel WL; Wolfe AR; Williams TM; Chen W
    Hum Pathol; 2021 Mar; 109():1-11. PubMed ID: 33245985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
    Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarcinoma.
    Shoucair S; Chen J; Martinson JR; Habib JR; Kinny-Köster B; Pu N; van Oosten AF; Javed AA; Shin EJ; Ali SZ; Lafaro KJ; Wolfgang CL; He J; Yu J
    JAMA Surg; 2022 Jul; 157(7):e221362. PubMed ID: 35612832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy:
    Soloff EV; Al-Hawary MM; Desser TS; Fishman EK; Minter RM; Zins M
    AJR Am J Roentgenol; 2022 Apr; 218(4):570-581. PubMed ID: 34851713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.
    Lee SM; Katz MH; Liu L; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
    Am J Surg Pathol; 2016 Dec; 40(12):1653-1660. PubMed ID: 27631521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
    Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
    Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma.
    Rowan DJ; Hartley CP; Aldakkak M; Christians KK; Evans DB; Tsai S; Hagen CE
    Ann Diagn Pathol; 2020 Jun; 46():151485. PubMed ID: 32172219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
    Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
    Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma.
    Haeberle L; Cacciato Insilla A; Kapp AC; Steiger K; Schlitter AM; Konukiewitz B; Demir IE; Friess H; Esposito I
    Histol Histopathol; 2021 Jul; 36(7):733-742. PubMed ID: 33769550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.
    Wei D; Zaid MM; Katz MH; Prakash LR; Kim M; Tzeng CD; Lee JE; Agrawal A; Rashid A; Wang H; Varadhachary G; Wolff RA; Tamm EP; Bhosale PR; Maitra A; Koay EJ; Wang H
    Pancreatology; 2021 Jan; 21(1):200-207. PubMed ID: 33221151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome.
    Das R; McGrath K; Seiser N; Smith K; Uttam S; Brand RE; Fasanella KE; Khalid A; Chennat JS; Sarkaria S; Singh H; Slivka A; Zeh HJ; Zureikat AH; Hogg ME; Lee KK; Paniccia A; Ongchin MC; Pingpank JF; Boone BA; Dasyam AK; Bahary N; Gorantla VC; Rhee JC; Thomas R; Ellsworth S; Landau MS; Ohori NP; Henn P; Shyu S; Theisen BK; Singhi AD
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):886-897. PubMed ID: 33278573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.
    Chatterjee D; Katz MH; Foo WC; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
    Am J Surg Pathol; 2017 Aug; 41(8):1097-1104. PubMed ID: 28614206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual Tumor Index: A Prognostically Significant Pathologic Parameter in Neoadjuvant-treated Pancreatic Ductal Adenocarcinoma.
    Panni RZ; Gonzalez I; Hartley CP; Williams GA; Liu J; Hawkins WG; Chatterjee D
    Am J Surg Pathol; 2018 Nov; 42(11):1480-1487. PubMed ID: 30179901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.
    Zhang Y; Huang ZX; Song B
    World J Gastroenterol; 2021 Jun; 27(22):3037-3049. PubMed ID: 34168406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
    J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.